Marshall Wace North America L.P. purchased a new stake in shares of Sanofi SA (NYSE:SNY) during the fourth quarter, Holdings Channel reports. The institutional investor purchased 27,439 shares of the company’s stock, valued at approximately $1,378,000.
Other hedge funds have also modified their holdings of the company. Pacitti Group Inc. purchased a new position in shares of Sanofi during the fourth quarter valued at $29,000. Tompkins Financial Corp purchased a new position in shares of Sanofi during the fourth quarter valued at $31,000. Carmichael Hill & Associates Inc. purchased a new position in shares of Sanofi during the fourth quarter valued at $44,000. Fieldpoint Private Securities LLC grew its holdings in shares of Sanofi by 110.2% during the fourth quarter. Fieldpoint Private Securities LLC now owns 992 shares of the company’s stock valued at $50,000 after buying an additional 520 shares in the last quarter. Finally, Evolution Wealth Advisors LLC grew its holdings in shares of Sanofi by 436.2% during the fourth quarter. Evolution Wealth Advisors LLC now owns 1,126 shares of the company’s stock valued at $57,000 after buying an additional 916 shares in the last quarter. Institutional investors and hedge funds own 7.04% of the company’s stock.
Shares of NYSE SNY opened at $41.37 on Thursday. The business’s 50-day moving average price is $47.13 and its two-hundred day moving average price is $47.31. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.22 and a quick ratio of 0.85. Sanofi SA has a one year low of $37.62 and a one year high of $51.84. The company has a market capitalization of $101.49 billion, a P/E ratio of 13.22, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67.
Sanofi (NYSE:SNY) last issued its earnings results on Thursday, February 6th. The company reported $0.74 EPS for the quarter, beating analysts’ consensus estimates of $0.70 by $0.04. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The firm had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $11.12 billion. On average, equities analysts anticipate that Sanofi SA will post 3.1 EPS for the current year.
A number of research analysts have recently weighed in on SNY shares. Argus lifted their price target on Sanofi from $52.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. DZ Bank reiterated a “neutral” rating on shares of Sanofi in a report on Friday, February 7th. SVB Leerink started coverage on Sanofi in a report on Tuesday, February 11th. They set a “market perform” rating and a $58.00 price target on the stock. Liberum Capital downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Wednesday, January 22nd. Finally, Zacks Investment Research downgraded Sanofi from a “buy” rating to a “hold” rating and set a $54.00 price target on the stock. in a report on Wednesday, February 19th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Sanofi presently has an average rating of “Buy” and a consensus price target of $55.00.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.